This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Impax moves for judgment against Humana in US generic drug case

( April 17, 2026, 21:37 GMT | Official Statement) -- MLex Summary: Impax Laboratories moved for a judgment against Humana’s US antitrust claims over generic drugs, saying Humana has failed to bring sufficient evidence that it conspired to fix prices and allocate markets for Lidocaine-Prilocaine or Digoxin, or that it participated in an “overarching conspiracy” involving nearly two dozen drugs. “Instead, the record shows that Impax made decisions about pricing, supply, and market share designed to maximize its own self-interest and that Impax often operated with imperfect information about its competitors’ next moves.”See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections